|
시장보고서
상품코드
1517287
세계의 PEG 3350 시장 : 제품 유형별, 연령별, 용도별, 유통 채널별, 지역별 예측(-2032년)Global PEG 3350 Market Research Report Information by Product Type by Age by Application by Distribution Channel, by Region - Forecast till 2032 |
||||||
PEG 3350 시장 규모는 2023년 19억 2,000만 달러, 2024년 20억 8,000만 달러에서 예측 기간 동안 6.63%의 연평균 복합 성장률(CAGR)로 2032년 37억 1,000만 달러 규모로 성장할 것으로 예측됩니다. 시장 성장의 원동력은 인도 및 기타 신흥 시장에서 대장암 유병률 증가, 전략적 이니셔티브 증가, 좌식 생활습관 및 운동 부족 증가로 인해 시장 성장을 주도하고 있습니다.
대장암은 전 세계적으로 증가하고 있습니다. 예를 들어, Lancet Regional Health Southeast Asia의 논문에 따르면 인도에서 대장암은 7번째로 발병률이 높은 암으로, 2021년에는 65,358명이 새로 발병할 것으로 예상됩니다. 전 세계 대장암 발병률은 증가 추세에 있으며, 현재 인구 10만 명당 19.5명, 인도는 15.2명입니다. 또한, 고칼로리, 저섬유질 식단, 육류 및 가공식품의 과다 섭취, 운동 부족 등 생활습관의 변화도 그 배경에 있습니다. 또한, 인도에서 대장암의 연령 성별 조정율은 20.6% 증가했으며, 50세 미만 성인의 수가 크게 증가하고 있습니다.
이러한 점으로 미루어 볼 때, PEG 3350 수요는 대장암 유병률 증가에 따라 증가할 것으로 예상되며, PEG 3350 시장은 대장암의 누적 유병률 외에도 예측 기간 동안 알코올 및 담배 제품 소비 증가, 흡연율 증가, 식습관 변화와 같은 생활 습관의 변화로 인해 견인될 것으로 예상됩니다. 견인할 것으로 예상됩니다.
지역별 전망
2022년 북미 PEG 3350 시장은 가장 높은 시장 점유율을 차지했습니다. 이는 북미에서 대장암, 당뇨병, 암, 신경 장애를 포함한 기타 질병의 유병률이 증가하고 있기 때문입니다.
유럽 시장은 두 번째로 높은 점유율을 보이고 있으며, 이는 대장암 유병률 증가와 유럽 전역의 좌식 생활습관 증가에 기인한 것으로 분석됩니다. 또한, 독일 PEG 3350 시장은 가장 큰 시장 점유율을 차지하고 있으며, 유럽에서 가장 빠르게 성장하는 시장이 될 것으로 예상되고 있습니다.
아시아태평양 시장은 2024년부터 2032년까지 크게 성장할 것으로 예상됩니다. 이는 이 지역의 대장암 유병률 증가, 좌식 생활습관, 운동 부족, 노인 인구 증가로 인한 것입니다. 국가별로는 중국이 가장 높은 점유율을 차지할 것으로 예상되며, 인도가 그 뒤를 이을 것으로 예상됩니다.
세계의 PEG 3350(PEG 3350) 시장을 조사했으며, 시장 정의와 개요, 시장 성장에 영향을 미치는 요인과 시장 기회 분석, 시장 규모 추이와 예측, 각종 부문별/지역별/주요 국가별 분석, 경쟁 환경, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.
목차
제1장 주요 요약
제2장 시장 개요
제3장 조사 방법
제4장 시장 역학
- 성장 촉진요인
- 성장 억제요인
- 기회
제5장 시장 요인 분석
- 밸류체인 분석
- Porter의 Five Forces 분석
- COVID-19가 세계의 PEG 3350 시장에 미치는 영향
제6장 세계의 PEG 3350 시장 : 제품 유형별
- 개요
- 분말
- BOWEL PREPARATION KIT
제7장 세계의 PEG 3350 시장 : 연령별
- 개요
- 소아
- 성인
- 고령자
제8장 세계의 PEG 3350 시장 : 용도별
- 개요
- 변비
- 의료 검사
- 대장 내시경 검사
- 바륨 관장 엑스레이 검사
- 수술
제9장 세계의 PEG 3350 시장 : 유통 채널별
- 개요
- 온라인 약국
- 오프라인 약국
제10장 세계의 PEG 3350 시장 : 지역별
- 개요
- 북미
- 유럽
- 아시아태평양
- 기타 지역
제11장 경쟁 구도
- 개요
- 경쟁 벤치마킹
- 세계의 PEG 3350 시장 주요 성장 전략
- 세계의 PEG 3350 시장 개발 건수 기준 주요 기업
- 주요 전개와 성장 전략
제12장 기업 개요
- TEVA PHARMACEUTICAL INDUSTRIES LTD.
- LGM PHARMA
- MCKESSON CORPORATION
- SISCO RESEARCH LABORATORIES PVT. LTD.
- BASF SE
- MERCK KGAA
- BAYER AG
- LUPIN PHARMACEUTICALS, INC.
- BRECKENRIDGE PHARMACEUTICAL, INC.
- PENDOPHARM
제13장 부록
LSH 24.08.02Global PEG 3350 Market Research Report Information by Product Type (Powder, Bowel Preparation Kit) by Age (Pediatric, Adult, and Geriatric) by Application (Constipation, Medical Tests, [Colonoscopy and Barium Enema X-Ray Examination], and Surgery) by Distribution Channel (Online Pharmacy, Offline Pharmacy), by Region (North America, Europe, Asia-Pacific, and Rest of the World) - Forecast till 2032
Market Overview
In 2023, the market size of PEG 3350 was estimated to be USD 1.92 billion. During the forecast period (2024-2032), the PEG 3350 Market industry is anticipated to experience a compound annual growth rate (CAGR) of 6.63%, increasing from USD 2.08 billion in 2024 to USD 3.71 billion by 2032. The market growth is being driven by the increasing prevalence of colon cancer in India and other developing nations, the increasing number of strategic initiatives, and the increasing sedentary lifestyle and physical inactivity.
Colon cancer is becoming more prevalent on a global scale. For example, the Lancet Regional Health Southeast Asia article indicates that colorectal cancer is the seventh most prevalent cancer in India, with 65,358 new cases in 2021. The global incidence of colon cancer has been on the rise, with a current rate of 19.5 per 100,000 population and 15.2 per 100,000 population in India. In the same vein, the evolving lifestyles that encompass the consumption of calorie-rich and low-fiber diets, the excessive consumption of red meat and processed foods, and physical inactivity. Additionally, the age-sex-adjusted rates of colon cancer in India have increased by 20.6%, with a significant increase in the number of adults under the age of 50.
Consequently, the demand for PEG 3350 is expected to rise in response to the increasing prevalence of colon cancer. The PEG 3350 markets are anticipated to be driven by the cumulative prevalence of colon cancer, as well as changing lifestyle habits, including the increasing consumption of alcohol and tobacco products, the rising rates of smoking, and poor dietary habits among the population, during the forecast period.
Market Segment Insights
Powder and digestive preparation kit-based market segmentation for the PEG 3350.
Age is the basis for market segmentation, which encompasses pediatric, adult, and geriatric categories.
The PEG 3350 Market segmentation is determined by the application, which encompasses medical tests and constipation. and surgery.
The market segmentation is determined by the distribution channels, which encompass both online and offline pharmacies.
Regional Perspectives
The market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World by region. In 2022, the North American PEG 3350 market held the highest market share. This is a result of the increasing prevalence of colorectal cancer and other diseases, including diabetes, cancer, and neurological disorders, in the North American region.
The second-largest market share in the Europe PEG 3350 market is attributed to the increasing prevalence of colorectal cancer and the increasing adoption of a sedentary lifestyle throughout the region. In addition, the German PEG 3350 Market was identified as the greatest market share and is anticipated to be the fastest-growing market in the European region.
It is anticipated that the Asia-Pacific PEG 3350 market will experience substantial growth from 2024 to 2032. This is a result of the increasing prevalence of colorectal cancer in the Asia-Pacific region, the adoption of sedentary lifestyles and physical inactivity, and the growing geriatric population. Additionally, it is anticipated that the China PEG 3350 Market will possess the highest market share, while India is anticipated to follow suit. The PEG 3350 Market is anticipated to be the fastest-growing market in the Asia-Pacific region.
The Middle East, Africa, and Latin America comprise the Rest of the World. The PEG 3350 Market in the regions is expected to experience growth as a result of the lack of awareness associated with the appropriate diet. Additionally, the research indicates that colorectal cancer is on the rise in the Middle East among young and older individuals, and it is a primary cause of frequent constipation in children, which is further contributing to the region's market growth.
Major Players
Teva Pharmaceutical Industries Ltd (Israel), LGM Pharma (US), McKesson Corporation (US), Sisco Research Laboratories Pvt. Ltd. (India), BASF SE (Germany), Merck KGaA (US), Bayer AG (Germany), Lupin Pharmaceuticals, Inc (India), Breckenridge Pharmaceutical, Inc. (US), and Pendopharm (Canada) are among the key companies in the PEG 3350 Market.
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
- 2.1 DEFINITION
- 2.2 SCOPE OF THE STUDY
- 2.3 RESEARCH OBJECTIVE
- 2.4 MARKET STRUCTURE
- 2.5 ASSUMPTIONS & LIMITATIONS
3 RESEARCH METHODOLOGY
- 3.1 DATA MINING
- 3.2 SECONDARY RESEARCH
- 3.3 PRIMARY RESEARCH
- 3.4 BREAKDOWN OF PRIMARY RESPONDENTS
- 3.5 FORECASTING TECHNIQUES
- 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
- 3.6.1 BOTTOM-UP APPROACH
- 3.6.2 TOP-DOWN APPROACH
- 3.7 DATA TRIANGULATION
- 3.8 VALIDATION
4 MARKET DYNAMICS
- 4.1 OVERVIEW
- 4.2 DRIVERS
- 4.2.1 RISING PREVALENCE OF COLON CANCER IN INDIA AND OTHER DEVELOPING NATIONS
- 4.2.2 RISING NUMBER OF STRATEGIC INITIATIVES
- 4.2.3 INCREASING SEDENTARY LIFESTYLE AND PHYSICAL INACTIVITY
- 4.3 RESTRAINTS
- 4.3.1 SIDE EFFECTS ASSOCIATED WITH PEG
- 4.3.2 INCREASING PREFERENCE FOR ORGANIC ALTERNATIVES
- 4.4 OPPORTUNITIES
- 4.4.1 ENTERING DEVELOPING MARKETS
5 MARKET FACTOR ANALYSIS
- 5.1 VALUE CHAIN ANALYSIS
- 5.1.1 R&D
- 5.1.2 MANUFACTURING
- 5.1.3 DISTRIBUTION
- 5.1.4 MARKETING & SALES
- 5.1.5 POST-SALES REVIEW/MONITORING
- 5.2 PORTER'S FIVE FORCES MODEL
- 5.2.1 THREAT OF NEW ENTRANTS
- 5.2.2 BARGAINING POWER OF SUPPLIERS
- 5.2.3 THREAT OF SUBSTITUTES
- 5.2.4 BARGAINING POWER OF BUYERS
- 5.2.5 INTENSITY OF RIVALRY
- 5.3 IMPACT OF COVID-19 ON THE GLOBAL PEG 3350 MARKET
- 5.3.1 IMPACT ON DEMAND
- 5.3.2 IMPACT ON SUPPLY CHAIN
- 5.3.3 IMPACT ON MARKET PLAYERS
6 GLOBAL PEG 3350 MARKET, BY PRODUCT TYPE
- 6.1 OVERVIEW
- 6.2 POWDER
- 6.3 BOWEL PREPARATION KIT
7 GLOBAL PEG 3350 MARKET, BY AGE
- 7.1 OVERVIEW
- 7.2 PEDIATRIC
- 7.3 ADULT
- 7.4 GERIATRIC
8 GLOBAL PEG 3350 MARKET, BY APPLICATION
- 8.1 OVERVIEW
- 8.2 CONSTIPATION
- 8.3 MEDICAL TESTS
- 8.3.1 COLONOSCOPY
- 8.3.2 BARIUM ENEMA X-RAY EXAMINATION
- 8.4 SURGERY
9 GLOBAL PEG 3350 MARKET, BY DISTRIBUTION CHANNEL
- 9.1 OVERVIEW
- 9.2 ONLINE PHARMACY
- 9.3 OFFLINE PHARMACY
10 GLOBAL PEG 3350 MARKET, BY REGION
- 10.1 OVERVIEW
- 10.2 NORTH AMERICA
- 10.2.1 US
- 10.2.2 CANADA
- 10.3 EUROPE
- 10.3.1 GERMANY
- 10.3.2 FRANCE
- 10.3.3 UK
- 10.3.4 ITALY
- 10.3.5 SPAIN
- 10.3.6 REST OF EUROPE
- 10.4 ASIA-PACIFIC
- 10.4.1 CHINA
- 10.4.2 INDIA
- 10.4.3 JAPAN
- 10.4.4 SOUTH KOREA
- 10.4.5 AUSTRALIA
- 10.4.6 REST OF ASIA-PACIFIC
- 10.5 REST OF THE WORLD
- 10.5.1 MIDDLE EAST
- 10.5.2 AFRICA
- 10.5.3 LATIN AMERICA
11 COMPETITIVE LANDSCAPE
- 11.1 OVERVIEW
- 11.2 COMPETITIVE BENCHMARKING
- 11.3 MAJOR GROWTH STRATEGY IN THE GLOBAL PEG 3350 MARKET
- 11.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL PEG 3350 MARKET
- 11.5 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 11.5.1 PRODUCT LAUNCH/PRODUCT APPROVAL
12 COMPANY PROFILES
- 12.1 TEVA PHARMACEUTICAL INDUSTRIES LTD.
- 12.1.1 COMPANY OVERVIEW
- 12.1.2 FINANCIAL ANALYSIS
- 12.1.3 PRODUCTS/SERVICES OFFERED
- 12.1.4 KEY DEVELOPMENTS
- 12.1.5 KEY STRATEGIES
- 12.2 LGM PHARMA
- 12.2.1 COMPANY OVERVIEW
- 12.2.2 FINANCIAL OVERVIEW
- 12.2.3 PRODUCTS/SERVICES OFFERED
- 12.2.4 KEY DEVELOPMENTS
- 12.2.5 KEY STRATEGIES
- 12.3 MCKESSON CORPORATION
- 12.3.1 COMPANY OVERVIEW
- 12.3.2 FINANCIAL OVERVIEW
- 12.3.3 PRODUCTS/SERVICES OFFERED
- 12.3.4 KEY DEVELOPMENTS
- 12.3.5 SWOT ANALYSIS
- 12.3.6 KEY STRATEGIES
- 12.4 SISCO RESEARCH LABORATORIES PVT. LTD.
- 12.4.1 COMPANY OVERVIEW
- 12.4.2 FINANCIAL OVERVIEW
- 12.4.3 PRODUCTS/SERVICES OFFERED
- 12.4.4 KEY DEVELOPMENTS
- 12.4.5 KEY STRATEGIES
- 12.5 BASF SE
- 12.5.1 COMPANY OVERVIEW
- 12.5.2 FINANCIAL OVERVIEW
- 12.5.3 PRODUCTS/SERVICES OFFERED
- 12.5.4 KEY DEVELOPMENTS
- 12.5.5 SWOT ANALYSIS
- 12.5.6 KEY STRATEGIES
- 12.6 MERCK KGAA
- 12.6.1 COMPANY OVERVIEW
- 12.6.2 FINANCIAL OVERVIEW
- 12.6.3 PRODUCTS OFFERED
- 12.6.4 KEY DEVELOPMENTS
- 12.6.5 SWOT ANALYSIS
- 12.6.6 KEY STRATEGIES
- 12.7 BAYER AG
- 12.7.1 COMPANY OVERVIEW
- 12.7.2 FINANCIAL OVERVIEW
- 12.7.3 PRODUCTS OFFERED
- 12.7.4 KEY DEVELOPMENTS
- 12.7.5 SWOT ANALYSIS
- 12.7.6 KEY STRATEGIES
- 12.8 LUPIN PHARMACEUTICALS, INC.
- 12.8.1 COMPANY OVERVIEW
- 12.8.2 FINANCIAL OVERVIEW
- 12.8.3 PRODUCTS OFFERED
- 12.8.4 KEY DEVELOPMENTS
- 12.8.5 SWOT ANALYSIS
- 12.8.6 KEY STRATEGIES
- 12.9 BRECKENRIDGE PHARMACEUTICAL, INC.
- 12.9.1 COMPANY OVERVIEW
- 12.9.2 FINANCIAL OVERVIEW
- 12.9.3 PRODUCTS OFFERED
- 12.9.4 KEY DEVELOPMENTS
- 12.9.5 KEY STRATEGIES
- 12.10 PENDOPHARM
- 12.10.1 COMPANY OVERVIEW
- 12.10.2 FINANCIAL OVERVIEW
- 12.10.3 PRODUCTS OFFERED
- 12.10.4 KEY DEVELOPMENTS
- 12.10.5 KEY STRATEGIES
13 APPENDIX
- 13.1 REFERENCES
- 13.2 RELATED REPORTS
